DreamCIS

DreamCIS FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of DreamCIS (223250.KQ) as of Oct 29, 2026 is 187.99 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -29.86 % — a change of -729.51% (higher).

FCF Conversion

187.99 %

YoY

-729.51%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of DreamCIS is 2025 187.99 % . FCF Conversion Rate (FCF/EBITDA) of DreamCIS was 2024 -29.86 % . It decreases by -729.51% higher compared to the previous year.

The DreamCIS FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
140.21 KRW
Jan 1, 2019
101.78 KRW
Jan 1, 2020
64.79 KRW
Jan 1, 2021
147.53 KRW
Jan 1, 2022
191.92 KRW
Jan 1, 2023
151.01 KRW
Jan 1, 2024
-29.86 KRW
Jan 1, 2025
187.99 KRW
The DreamCIS FCF Conversion history
YEARFCF ConversionYoY
187.99 %-729.51%
-29.86 %-119.78%
151.01 %-21.32%
191.92 %+30.09%
147.53 %+127.70%
64.79 %-36.34%
101.78 %-27.41%
140.21 %-195.15%
-147.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DreamCIS Stock analysis

What does DreamCIS do? DreamCIS Inc. is a company based in Seoul, South Korea, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company went public on May 22, 2020, with its stock listed under the ticker 223250.KQ and ISIN KR7223250002. DreamCIS Inc. provides clinical online information and consultation services, focusing on regulatory post-marketing surveillance (rPMS), clinical trials, and non-interventional studies (NIS). The company serves both domestic and international markets, offering its services to clients seeking support in clinical research and regulatory compliance. Its headquarters are located in Seoul, South Korea. The company's website is http://www.dreamcis.com/, which serves as a primary source for further information about its services and operations. DreamCIS Inc. does not provide detailed information about its founding year, specific leadership, or financial figures beyond its IPO date, and no acquisitions or additional product names are mentioned in the provided data. The company's services are primarily aimed at facilitating clinical research and ensuring adherence to regulatory standards in the life sciences sector. DreamCIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DreamCIS stock

FCF Conversion Rate (FCF/EBITDA) of DreamCIS is 187.99 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of DreamCIS changed from -29.86 % to 187.99 %, representing a -729.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) DreamCIS since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s DreamCIS with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — DreamCIS

All Key Metrics — DreamCIS